Liztox (botulinum toxin type A) / Huons - LARVOL DELTA

To Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy (clinicaltrials.gov) - P3 | N=188 | Active, not recruiting | Sponsor: Huons Biopharma | Recruiting ➔ Active, not recruiting | Trial primary completion date: Nov 2024 ➔ Mar 2024

Enrollment closed • Trial primary completion date

A Randomized, Double-Blind, Active Control, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Liztox versus Botox in Post-Stroke Upper Limb Spasticity. (PubMed, Toxins (Basel)) - "No safety-related concerns were reported during the study. In conclusion, Liztox injection proved to be a secure and efficacious intervention for managing upper extremity spasticity in post-stroke patients."

Clinical • Journal • P3 data • Cardiovascular • Movement Disorders

To Evaluate HU-014 in the Treatment of Post Stroke Upper Limb (clinicaltrials.gov) - P3 | N=198 | Completed | Sponsor: Huons Co., Ltd. | Recruiting ➔ Completed

Trial completion • Cardiovascular • Movement Disorders

To Evaluate the Efficacy and Safety of LIZTOX in Subjects With Benign Masseteric Hypertrophy (clinicaltrials.gov) - P3 | N=168 | Recruiting | Sponsor: Huons Biopharma

New P3 trial

To Evaluate HU-014 in the Treatment of Post Stroke Upper Limb (clinicaltrials.gov) - P3 | N=198 | Recruiting | Sponsor: Huons Co., Ltd.

New P3 trial • Cardiovascular • Movement Disorders

A Phase I Clinical Trial to Evaluate the Safety of HU-045 for Treating Moderate to Severe Glabellar Lines: A Pilot Study. (PubMed, J Eur Acad Dermatol Venereol) - "HU-045 is a Clostridium BoNTA (150 kDa) preparation comprising the same molecular components as the existing incobotulinumtoxinA. However, the efficacy and safety of HU-045 have not been explored. Accordingly, we performed a phase I clinical study to evaluate the safety and efficacy of HU-045 in the treatment of moderate-to-severe glabellar lines."

Clinical • Journal • P1 data